Zura Bio (NASDAQ:ZURA) Stock Price Down 7.9% – Time to Sell?

Zura Bio Limited (NASDAQ:ZURA)’s share price dropped 7.9% during mid-day trading on Wednesday . The company traded as low as $5.51 and last traded at $5.4310. 142,710 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 831,630 shares. The stock had previously closed at $5.90.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Wednesday, April 8th. Chardan Capital boosted their target price on Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Wedbush restated an “outperform” rating and set a $15.00 price target on shares of Zura Bio in a research note on Wednesday. Finally, Oppenheimer lowered their price target on Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday, March 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Price Performance

The company has a market capitalization of $490.53 million, a PE ratio of -4.74 and a beta of -0.03. The stock’s 50 day simple moving average is $4.46 and its 200-day simple moving average is $5.30.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.05). On average, equities analysts predict that Zura Bio Limited will post -0.76 earnings per share for the current year.

Hedge Funds Weigh In On Zura Bio

Several institutional investors have recently modified their holdings of the business. Bank of America Corp DE increased its position in shares of Zura Bio by 3,007.7% during the first quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock worth $812,000 after acquiring an additional 132,130 shares during the period. Stempoint Capital LP purchased a new position in Zura Bio in the first quarter valued at $4,483,000. ADAR1 Capital Management LLC boosted its holdings in Zura Bio by 12.2% in the first quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock valued at $3,751,000 after purchasing an additional 68,338 shares during the period. EcoR1 Capital LLC purchased a new position in Zura Bio in the first quarter valued at $7,019,000. Finally, Commodore Capital LP acquired a new position in Zura Bio during the 1st quarter worth $19,338,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.